LC-MS/MS Analysis in Toxicology: GLP Best Practices

Analytical precision is of utmost importance in toxicological studies. Today, advanced bioanalytical methodologies are significantly impacting the reliability of studies, the success of pharmaceuticals, and the regulatory approval process. LC-MS/MS analysis is a robust platform for bioanalysis in GLP-compliant toxicity assessments. It combines chromatographic techniques with tandem mass spectrometry to offer enhanced sensitivity and selectivity. LC-MS/MS systems employ mass spectrometry assays for unique applications, including biomarker analysis, toxicokinetic studies, metabolite identification, and Cytokine Analysis.

A comprehensive LC-MS method development following GLP compliance ensures data integrity and approvals, which are essential for the success of drug development programs. This article explores GLP best practices and analytical strategies for LC-MS/MS toxicology applications.

Toxicological studies

Toxicity assessments are critical for product development and regulatory approval. The US FDA requires conducting nonclinical toxicological studies in a minimum of two species: one rodent, one non-rodent. These studies are conducted under GLP regulations to ensure control of test subjects and reliability of generated data. Most novel compounds may show toxicity when administered at higher doses. Toxicokinetic studies and preclinical toxicity assessments help researchers determine the safety profiles of a drug candidate for subsequent human trials.

Adverse events observed during preclinical studies help researchers assess organisms for unsafe or undesirable effects. Understanding the effects on target organs can help relate toxicity with drug effects and monitor them in patients to withdraw or limit the use of therapeutics. Hence, toxicokinetics and preclinical toxicity assessments are vital in understanding the reversibility and toxicity of drug compounds on animal subjects and human participants. Toxicokinetic assessments study wide dose ranges and evaluate their relation with systemic exposure. Hence, they are critical in determining exposure linearity with metabolic saturations, steady-state exposures, potential adverse events, and compound accumulation in organs.

GLP-compliant LC-MS/MS analysis

Nonclinical and clinical method development does not need GLP compliance. However, adequate documentation of protocols and systems is critical to support subsequent method validation. Method development focused on defining the desired method and evidence of method suitability for the intended applications. If method development experiments, including aspects such as accuracy, stability, precision, etc, are incorporated, then the method design is ready for validation.

Regulatory guidelines for method validation require validating parameters defined in a study plan or protocol. These parameters include selectivity, accuracy, precision, sensitivity, linearity, reproducibility, limit of quantitation, stability, and dynamic range. Method validation may comprise multiple analytes, single analytes, or a parent and its metabolites. In any circumstance, sponsors should conduct method validation in the same matrix used for analyzing study samples. During validation, sponsors should prepare stability samples, quality controls, and calibration standards by spiking a blank biological matrix with the analyte of interest. Additionally, for chromatographic methods, sponsors add suitable internal standards during sample processing. During method validation, sponsors should evaluate carryover using two blanks following calibration standards or high-quality controls. 

Must Read: ELISA Assays in Drug Discovery: Role and Importance

A full method validation is required when sponsors implement assays for the very first time or when they add additional metabolite or analyte assessments. On the other hand, a partial method validation is needed when the assay is transferred, the software, instrumentation, or detection system is changed, the protocol is modified, the species is modified within the matrix, the matrix is modified within species, standard curve concentration is modified, or selectivity evaluations are needed for concomitant medications or metabolites. Notably, sponsors conduct partial validation when the ion in the anticoagulant counter changes from potassium to sodium, but not when the changes occur in counter ion stoichiometry from K2 to K3.

For nonclinical studies, sponsors conduct a full validation first in rats due to enhanced care towards known enzymatic effects. A partial method validation is needed for the second species. On the other hand, full validation is mandatory for clinical studies. When validating matrices such as from human urine to human plasma, a full method validation is critical to assess accuracy, selectivity, precision, and stability. For minor modifications within the same calibration range and matrix, sponsors may perform a partial validation.

Bioanalytical assay validation in the United States does not need GLP compliance. However, several regulatory guidelines are available to design method validation protocols. Although GLP compliances are not required in the US for method validation, following GLP regulations during method validation of clinical analysis can offer an enhanced quality system structure, which can augment documentation details and help advance the planning and execution of relevant data if required for regulatory purposes. Hence, GLP guidelines for LC-MS/MS analysis follow the same suit, where adhering to GLP regulations may prove beneficial to demonstrate reliability and suitability in case any relevant situation arises in the future.

Conclusion

GLP best practices are essential in LC-MS/MS analysis to ensure data integrity and regulatory compliance. Validated LC-MS/MS analysis is vital in supporting safety assessments and regulatory submissions. A comprehensive LC-MS method development and specialized LC-MS services enable drug developers to fulfill regulatory requirements and meet deadlines. Hence, GLP-compliant LC-MS/MS services can enhance regulatory approvals and accelerate developmental timelines.